Payment overview · 2025
General Payments
$659.15
47 reported records · 9 companies
Healthcare provider profile · identity verified
James Wilson Hurst, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1154376374
Verified facts
What the public records show
CMS Open Payments records show James Wilson Hurst, MD received $659.15 in general payments during 2025 across 47 reported records.
ABBVIE INC. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.49 | 31.8% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.27 | 24.9% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $121.33 | 18.4% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.49 | 9.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.30 | 5.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.62 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.68 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.87 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.10 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $659.15 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $164.27 | 18 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $164.27 | 18 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $121.33 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.82 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.67 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.43 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.49 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 119 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
84 | 77 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 890 | 258 |
| Levothyroxine Sodium | Levothyroxine Sodium | 825 | 213 |
| Omeprazole | Omeprazole | 567 | 172 |
| Gabapentin | Gabapentin | 478 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 118 |
| Lisinopril | Lisinopril | 377 | 105 |
| Furosemide | Furosemide | 256 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 256 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 244 | 62 |
| Famotidine | Famotidine | 232 | 62 |
| Alendronate Sodium | Alendronate Sodium | 218 | 60 |
| Metformin Hcl | Metformin Hcl | 210 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 58 |
| Losartan Potassium | Losartan Potassium | 195 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 56 |
| Trazodone Hcl | Trazodone Hcl | 170 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 50 |
| Simvastatin | Simvastatin | 169 | 46 |
| Meloxicam | Meloxicam | 167 | 55 |
| Mirtazapine | Mirtazapine | 166 | 43 |
| Allopurinol | Allopurinol | 163 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 162 | 44 |
| Alprazolam | Alprazolam | 159 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 44 |
| Montelukast Sodium | Montelukast Sodium | 154 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 43 |
| Potassium Chloride | Potassium Chloride | 142 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 35 |
| Sertraline Hcl | Sertraline Hcl | 134 | 41 |
| Glipizide Er | Glipizide | 132 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 32 |
| Metformin Hcl Er | Metformin Hcl | 130 | 41 |
| Eliquis | Apixaban | 119 | 32 |
| Enalapril Maleate | Enalapril Maleate | 107 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 23 |
| Tramadol Hcl | Tramadol Hcl | 100 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 31 |
| Benazepril Hcl | Benazepril Hcl | 87 | 23 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 84 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 23 |
| Synthroid | Levothyroxine Sodium | 78 | 19 |
| Jardiance | Empagliflozin | 76 | 16 |
| Lovastatin | Lovastatin | 76 | 21 |
| Buspirone Hcl | Buspirone Hcl | 74 | 29 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 73 | 73 |
| Carvedilol | Carvedilol | 71 | 20 |
| Clonazepam | Clonazepam | 70 | 12 |
| Fenofibrate | Fenofibrate | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 19 |
| Glipizide | Glipizide | 68 | 18 |
| Irbesartan | Irbesartan | 68 | 18 |
| Donepezil Hcl | Donepezil Hcl | 67 | 27 |
| Ezetimibe | Ezetimibe | 65 | 20 |
| Meclizine Hcl | Meclizine Hcl | 65 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 62 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 20 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Ozempic | Semaglutide | 55 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 13 |
| Atenolol | Atenolol | 49 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Clonidine Hcl | Clonidine Hcl | 47 | 16 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 14 |
| Nystatin | Nystatin | 42 | 21 |
| Valsartan | Valsartan | 42 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Estradiol | Estradiol | 40 | 12 |
| Celecoxib | Celecoxib | 39 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 16 |
| Methylprednisolone | Methylprednisolone | 37 | 30 |
| Ramipril | Ramipril | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 12 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Baclofen | Baclofen | 31 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 25 |
| Fluconazole | Fluconazole | 30 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Prednisone | Prednisone | 18 | 12 |
| Novolog | Insulin Aspart | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Colchicine | Colchicine | 15 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Glyburide | Glyburide | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine Hcl Er | Clonidine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $659.15 · 47 records | ABBVIE INC. | CAMZYOS, ELIQUIS, FREESTYLE LIBRE 3, LEQVIO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error